Menadione Sodium Bisulfite Injection Market, Global Outlook and Forecast 2025-2032

2025-07-11
By: siddheshkapshikar
Posted in: ddd

According to the latest market intelligence from Intel Market Research , the global Menadione Sodium Bisulfite Injection market was valued at USD 126 million in 2024 and is projected to reach USD 178 million by 2032 , growing at a steady CAGR of 5.1% during the forecast period (2025–2032). This growth trajectory reflects the critical role of vitamin K supplementation in managing coagulation disorders and the increasing global burden of liver-related conditions.

What is Menadione Sodium Bisulfite Injection?

Menadione Sodium Bisulfite Injection is a water-soluble synthetic form of vitamin K3 , clinically administered to treat and prevent hemorrhagic conditions caused by vitamin K deficiency. As an essential cofactor for γ-carboxylation of clotting factors II, VII, IX, and X , it rapidly restores hemostasis by activating the coagulation cascade. The therapy is particularly vital for:

Neonatal hemorrhagic disease prevention (given that newborns have sterile guts and limited vitamin K stores)
Bleeding management in liver cirrhosis patients (who often exhibit impaired vitamin K absorption)
Antidote for warfarin overdose (counteracting the anticoagulant effects)

Available in 2mg/ml and 4mg/ml formulations, these injections are primarily administered in hospital and clinical settings across North America, Europe, and emerging Asian markets.

Download FREE Sample Report :
Menadione Sodium Bisulfite Injection Market - View in Detailed Research Report

Key Market Drivers

1. Rising Prevalence of Liver Disorders Worldwide

The global surge in liver cirrhosis cases —projected to affect over 1.5% of the global population by WHO estimates—is significantly driving demand. Chronic liver disease patients frequently develop coagulopathies due to malabsorption of fat-soluble vitamins, creating sustained need for parenteral vitamin K therapy.

2. Expanding Neonatal Care Infrastructure

With the American Academy of Pediatrics and WHO recommending routine vitamin K prophylaxis for newborns, healthcare systems globally are incorporating Menadione Sodium Bisulfite protocols. Emerging economies are witnessing 12-15% annual growth in neonatal intensive care units, further propelling market expansion.

3. Increased Anticoagulant Use and Reversal Needs

The global anticoagulant market's 7.8% CAGR (2020-2027) directly correlates with rising demand for reversal agents. While newer agents like andexanet alfa exist, Menadione remains cost-effective for warfarin reversal in mid-income healthcare systems.

Market Challenges

Despite clinical importance, the sector faces hurdles:

Regulatory scrutiny on synthetic vitamin K safety : Some agencies restrict high doses due to potential neonatal hemolysis risks
Competition from phytonadione (Vitamin K1) : Often preferred for chronic deficiency management
Cold chain requirements : Light-sensitive nature necessitates specialized storage solutions

Innovation and Growth Opportunities

Market players are capitalizing on several strategic fronts:

Combination therapies : Developing injections with clotting factor concentrates for severe hemorrhages
Emerging market expansion : Countries like India and Brazil show 18-22% year-on-year growth in critical care admissions
Lyophilized formulations : Enhancing stability for tropical climates

Notably, Sinopharm Ronshyn Pharmaceutical launched a next-generation stabilization technology in 2023, extending shelf-life by 40% - a development anticipated to capture 15-20% of the hospital segment by 2026.

Regional Market Landscape

North America : Accounts for ~35% market share, driven by advanced neonatal care protocols and anticoagulant usage
Europe : Stringent guidelines on vitamin K prophylaxis sustain steady demand
Asia-Pacific : Fastest growing region (7.2% CAGR) due to healthcare infrastructure development
Latin America/MENA : Increasing adoption in military medicine and trauma centers

Market Segmentation

By Type

2mg/ml
4mg/ml

By Application

Hospital
Clinic
Other Healthcare Settings

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East & Africa

Get Full Report Here :
Menadione Sodium Bisulfite Injection Market - View in Detailed Research Report

Competitive Intelligence

The market features established pharmaceutical manufacturers with GMP-certified production facilities:

Shanghai Xiandai Hasen Pharmaceutical (China)
Suicheng Pharmaceutical (China)
Chengdu Brilliant Pharmaceutical (China)
Sinopharm Ronshyn Pharmaceutical (China)
Vernal Biotech (India)
American Remedies (USA)

Recent developments include Xi'an Lijun Pharmaceutical's 2023 capacity expansion and Hindustan Medicines' FDA pre-qualification for African market entry.

Report Insights

The comprehensive market analysis provides:

Patent expiry impact analysis (2025-2027)
Pricing strategy benchmarking across 25 countries
Clinical trial pipeline assessment
Supply chain optimization models
Regulatory scenario forecasting

About Intel Market Research

Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology , pharmaceuticals , and healthcare infrastructure . Our research capabilities include: